COPLAND ROAD CAPITAL NEW

Research COPLAND ROAD CAPITAL NEW (A2P) on Bullrun: valuation model: 4.9% undervalued, market cap EUR 610.69M, P/E 16.9, dividend yield 3.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerA2P
• ExchangeF
• CountryPoland
• SectorHealthcare
• IndustryMedical Devices
• CurrencyEUR
• Valuation signal4.9% undervalued
• Market capEUR 610.69M
• P/E16.9
• Dividend yield3.6%
• Financial periodQ4 2025
• RevenueEUR 227.98M
• Net incomeEUR 34.97M
• Free cash flowEUR 95.07M
• Gross margin34.0%

Valuation Snapshot

Bullrun's latest valuation model marks COPLAND ROAD CAPITAL NEW as 4.9% undervalued; latest market cap is EUR 610.69M; P/E is 16.9; dividend yield is 3.6%.

About COPLAND ROAD CAPITAL NEW

Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics for oncology.

Frequently asked questions

Is COPLAND ROAD CAPITAL NEW overvalued or undervalued?

Bullrun's valuation model currently marks COPLAND ROAD CAPITAL NEW as 4.9% undervalued.

What is COPLAND ROAD CAPITAL NEW's market cap?

COPLAND ROAD CAPITAL NEW's market capitalization is EUR 610.69M.

What is COPLAND ROAD CAPITAL NEW's P/E ratio?

COPLAND ROAD CAPITAL NEW's price-to-earnings (P/E) ratio is 16.9.

Does COPLAND ROAD CAPITAL NEW pay a dividend?

COPLAND ROAD CAPITAL NEW has a dividend yield of 3.6%.

What does COPLAND ROAD CAPITAL NEW do?

Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine.